Skip to main content
Erschienen in: Journal of Gastroenterology 11/2019

25.06.2019 | Original Article—Alimentary Tract

Relationship between Barrett’s esophagus and colonic diseases: a role for colonoscopy in Barrett’s surveillance

verfasst von: Yuji Amano, Ryotaro Nakahara, Takafumi Yuki, Daisuke Murakami, Tetsuro Ujihara, Iwaki Tomoyuki, Ryota Sagami, Satoshi Suehiro, Yasushi Katsuyama, Kenji Hayasaka, Hideaki Harada, Yasumasa Tada, Youichi Miyaoka, Hirofumi Fujishiro

Erschienen in: Journal of Gastroenterology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Given that risk factors for Barrett’s carcinogenesis are predictive, appropriate management and surveillance of Barrett’s esophagus (BE) may be provided. The presence of colorectal neoplasms (CRNs) is a possible predictor of the development of BE and the progression to esophageal adenocarcinoma (EAC). We evaluated the relationship between BE or EAC and colonic diseases, including neoplasms and diverticulosis.

Methods

Patients (N = 5606) who underwent both colonoscopy and esophagogastroduodenoscopy between January 2016 and December 2017 at three institutions were enrolled. The relationships between the presence of colonic diseases and BE or EAC and other clinical or endoscopic predictors of the presence of BE were investigated retrospectively.

Results

The prevalence of BE ≥ 1 cm and ≥ 3 cm in length was 13.0% and 0.52%, respectively. BE was closely related with the presence of colorectal adenoma (48.4% vs. 37.2% in non-BE; P < 0.001), adenocarcinoma (16.6% vs. 8.4%, P < 0.001) and colonic diverticulosis (CD) (34.1% vs. 29.3%, P < 0.001). In patients with long-segment BE, CRNs (79.3%, P < 0.001) and CD (48.2%, P = 0.038) were more common. EAC patients also had a statistically significantly higher incidence of CRNs than non-BE patients (87.5% vs. 45.6%, P = 0.027). Diverticulosis at the distal colon correlated significantly with EAC and BE (50.0%, P = 0.010 and 15.4%, P = 0.024, vs. 12.0% in non-BE). Multivariate analysis showed that CRNs (t = 8.55, P < 0.001), reflux esophagitis (t = 5.26, P < 0.001) and hiatal hernia (t = 11.68, P < 0.001) were predictors of BE.

Conclusions

The presence of CRNs was strongly associated with BE and EAC. Therefore, colonoscopy may be useful for establishing a strategy for the surveillance of BE.
Literatur
1.
Zurück zum Zitat Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–86.PubMedCrossRef Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–86.PubMedCrossRef
2.
Zurück zum Zitat Caygill CP, Royston C, Charlett A, et al. Mortality in Barrett's esophagus: three decades of experience at a single center. Endoscopy. 2012;44:892–8.PubMedCrossRef Caygill CP, Royston C, Charlett A, et al. Mortality in Barrett's esophagus: three decades of experience at a single center. Endoscopy. 2012;44:892–8.PubMedCrossRef
3.
4.
Zurück zum Zitat Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012;61:970–6.PubMedCrossRef Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012;61:970–6.PubMedCrossRef
5.
Zurück zum Zitat Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, et al. An accurate cancer incidence in Barrett's esophagus: a best estimate using published data and modeling. Gastroenterology. 2015;149:577–85.PubMedCrossRef Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, et al. An accurate cancer incidence in Barrett's esophagus: a best estimate using published data and modeling. Gastroenterology. 2015;149:577–85.PubMedCrossRef
6.
Zurück zum Zitat Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2018;17:864–8.PubMedCrossRefPubMedCentral Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2018;17:864–8.PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Matsuhashi N, Sakai E, Ohata K, et al. Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan. J Gastroenterol Hepatol. 2017;32:409–14.PubMedCrossRef Matsuhashi N, Sakai E, Ohata K, et al. Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan. J Gastroenterol Hepatol. 2017;32:409–14.PubMedCrossRef
8.
Zurück zum Zitat Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7–42.PubMedCrossRef Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7–42.PubMedCrossRef
9.
Zurück zum Zitat Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111:30–50.PubMedCrossRef Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111:30–50.PubMedCrossRef
10.
Zurück zum Zitat Cooper S, Menon S, Nightingale P, et al. Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study. United Euro Gastroenterol J. 2014;2:91–8.CrossRef Cooper S, Menon S, Nightingale P, et al. Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study. United Euro Gastroenterol J. 2014;2:91–8.CrossRef
11.
Zurück zum Zitat Krishnamoorthi R, Borah B, Heien H, et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc. 2016;84:40–6.PubMedPubMedCentralCrossRef Krishnamoorthi R, Borah B, Heien H, et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc. 2016;84:40–6.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014;63:220–9.PubMed El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014;63:220–9.PubMed
13.
Zurück zum Zitat Siersema PD, Yu S, Sahbaie P, et al. Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc. 2006;63:581–6.PubMedCrossRef Siersema PD, Yu S, Sahbaie P, et al. Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc. 2006;63:581–6.PubMedCrossRef
14.
Zurück zum Zitat Andrici J, Tio M, Cox MR, Eslick GD. Meta-analysis: Barrett’s oesophagus and the risk of colonic tumours. Aliment Pharmacol. Ther. 2013;37:401–10.PubMedCrossRef Andrici J, Tio M, Cox MR, Eslick GD. Meta-analysis: Barrett’s oesophagus and the risk of colonic tumours. Aliment Pharmacol. Ther. 2013;37:401–10.PubMedCrossRef
15.
Zurück zum Zitat Sonnenberg A, Genta RM. Barrett's metaplasia and colonic neoplasms: a significant association in a 203,534-patient study. Dig Dis Sci. 2013;58:2046–51.PubMedCrossRef Sonnenberg A, Genta RM. Barrett's metaplasia and colonic neoplasms: a significant association in a 203,534-patient study. Dig Dis Sci. 2013;58:2046–51.PubMedCrossRef
16.
Zurück zum Zitat Laitakari R, Laippala P, Isolauri J. Barrett's oesophagus is not a risk factor for colonic neoplasia: a case-control study. Ann Med. 1995;27:499–502.PubMedCrossRef Laitakari R, Laippala P, Isolauri J. Barrett's oesophagus is not a risk factor for colonic neoplasia: a case-control study. Ann Med. 1995;27:499–502.PubMedCrossRef
17.
Zurück zum Zitat Murphy SJ, Anderson LA, Mainie I, et al. Incidence of colorectal cancer in a population-based cohort of patients with Barrett's oesophagus. Scand J Gastroenterol. 2005;40:1449–533.PubMed Murphy SJ, Anderson LA, Mainie I, et al. Incidence of colorectal cancer in a population-based cohort of patients with Barrett's oesophagus. Scand J Gastroenterol. 2005;40:1449–533.PubMed
18.
Zurück zum Zitat Katanoda K, Hori M, Matsuda T, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.PubMedCrossRef Katanoda K, Hori M, Matsuda T, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.PubMedCrossRef
19.
Zurück zum Zitat Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.PubMedPubMedCentralCrossRef Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.CrossRef Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.CrossRef
21.
Zurück zum Zitat Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.PubMedCrossRef Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.PubMedCrossRef
22.
Zurück zum Zitat Ishimura N, Amano Y, Kinoshita Y. Endoscopic definition of esophagogastric junction for diagnosis of Barrett's esophagus: importance of systematic education and training. Dig Endosc. 2009;21:213–8.PubMedCrossRef Ishimura N, Amano Y, Kinoshita Y. Endoscopic definition of esophagogastric junction for diagnosis of Barrett's esophagus: importance of systematic education and training. Dig Endosc. 2009;21:213–8.PubMedCrossRef
23.
Zurück zum Zitat Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206–11.PubMedCrossRef Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206–11.PubMedCrossRef
24.
Zurück zum Zitat Okita K, Amano Y, Takahashi Y, et al. Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol. 2008;43:928–34.PubMedCrossRef Okita K, Amano Y, Takahashi Y, et al. Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol. 2008;43:928–34.PubMedCrossRef
25.
Zurück zum Zitat Amano Y, Kinoshita Y. Barrett esophagus: perspectives on its diagnosis and management in asian populations. Gastroenterol Hepatol (N Y). 2008;4:45–53. Amano Y, Kinoshita Y. Barrett esophagus: perspectives on its diagnosis and management in asian populations. Gastroenterol Hepatol (N Y). 2008;4:45–53.
26.
Zurück zum Zitat Sharara AI, El-Halabi MM, Mansour NM, et al. Alcohol consumption is a risk factor for colonic diverticulosis. J Clin Gastroenterol. 2013;47:420–5.PubMedCrossRef Sharara AI, El-Halabi MM, Mansour NM, et al. Alcohol consumption is a risk factor for colonic diverticulosis. J Clin Gastroenterol. 2013;47:420–5.PubMedCrossRef
27.
Zurück zum Zitat Comstock SS, Lewis MM, Pathak DR, et al. Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosis. PLoS ONE. 2014;9:e95232.PubMedPubMedCentralCrossRef Comstock SS, Lewis MM, Pathak DR, et al. Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosis. PLoS ONE. 2014;9:e95232.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Masuda A, Fujita T, Murakami M, et al. Influence of hiatal hernia and male sex on the relationship between alcohol intake and occurrence of Barrett's esophagus. PLoS ONE. 2018;13:e0192951.PubMedPubMedCentralCrossRef Masuda A, Fujita T, Murakami M, et al. Influence of hiatal hernia and male sex on the relationship between alcohol intake and occurrence of Barrett's esophagus. PLoS ONE. 2018;13:e0192951.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152:1656–70.PubMedCrossRef Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152:1656–70.PubMedCrossRef
30.
Zurück zum Zitat Bollschweiler E, Schloesser T, Leers J, et al. High prevalence of colonic polyps in white males with esophageal adenocarcinoma. Dis Colon Rectum. 2009;52:299–304.PubMedCrossRef Bollschweiler E, Schloesser T, Leers J, et al. High prevalence of colonic polyps in white males with esophageal adenocarcinoma. Dis Colon Rectum. 2009;52:299–304.PubMedCrossRef
31.
Zurück zum Zitat Kumaravel A, Thota PN, Lee HJ, et al. Higher prevalence of colon polyps in patients with Barrett's esophagus: a case-control study. Gastroenterol Rep (Oxf). 2014;2:281–7.PubMedPubMedCentralCrossRef Kumaravel A, Thota PN, Lee HJ, et al. Higher prevalence of colon polyps in patients with Barrett's esophagus: a case-control study. Gastroenterol Rep (Oxf). 2014;2:281–7.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Greer KB, Falk GW, Bednarchik B, et al. Associations of serum adiponectin and leptin with Barrett's Esophagus. Clin Gastroenterol Hepatol. 2015;13:2265–72.PubMedPubMedCentralCrossRef Greer KB, Falk GW, Bednarchik B, et al. Associations of serum adiponectin and leptin with Barrett's Esophagus. Clin Gastroenterol Hepatol. 2015;13:2265–72.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Kawashima K, Maeda K, Saigo C, et al. Adiponectin and intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci. 2017;18:866.PubMedCentralCrossRef Kawashima K, Maeda K, Saigo C, et al. Adiponectin and intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci. 2017;18:866.PubMedCentralCrossRef
34.
Zurück zum Zitat Wang D, Gao L, Gong K, et al. Increased serum leptin level in overweight patients with colon carcinoma: a cross-sectional and prospective study. Mol Clin Oncol. 2017;6:75–8.PubMedCrossRef Wang D, Gao L, Gong K, et al. Increased serum leptin level in overweight patients with colon carcinoma: a cross-sectional and prospective study. Mol Clin Oncol. 2017;6:75–8.PubMedCrossRef
35.
Zurück zum Zitat Georgopoulos SD, Polymeros D, Triantafyllou K, et al. Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion. 2006;74:42–6.PubMedCrossRef Georgopoulos SD, Polymeros D, Triantafyllou K, et al. Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion. 2006;74:42–6.PubMedCrossRef
36.
37.
Zurück zum Zitat Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase- 2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci. 2006;51:779–87.PubMedCrossRef Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase- 2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci. 2006;51:779–87.PubMedCrossRef
38.
Zurück zum Zitat Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett’s carcinogenesis. Clin Cancer Res. 2004;10:4784–92.PubMedCrossRef Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett’s carcinogenesis. Clin Cancer Res. 2004;10:4784–92.PubMedCrossRef
39.
Zurück zum Zitat Wang JS, Varro A, Lightdale CJ, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett’s esophagus. Am J Gastroenterol. 2010;105:1039–45.PubMedCrossRef Wang JS, Varro A, Lightdale CJ, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett’s esophagus. Am J Gastroenterol. 2010;105:1039–45.PubMedCrossRef
40.
Zurück zum Zitat Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–8.PubMedCrossRef Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–8.PubMedCrossRef
41.
Zurück zum Zitat Yang YX, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748–54.PubMedCrossRef Yang YX, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748–54.PubMedCrossRef
42.
Zurück zum Zitat Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755–60.PubMedCrossRef Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755–60.PubMedCrossRef
43.
Zurück zum Zitat Obszynska JA, Atherfold PA, Nanji M, et al. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett’s oesophagus in vivo. Gut. 2010;59:156–63.PubMedCrossRef Obszynska JA, Atherfold PA, Nanji M, et al. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett’s oesophagus in vivo. Gut. 2010;59:156–63.PubMedCrossRef
44.
Zurück zum Zitat Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013;11:382–8.PubMedCrossRef Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013;11:382–8.PubMedCrossRef
45.
Zurück zum Zitat Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–377.PubMedCrossRef Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–377.PubMedCrossRef
46.
Zurück zum Zitat Ou J, DeLany JP, Zhang M, et al. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer. 2012;64:34–40.PubMedCrossRef Ou J, DeLany JP, Zhang M, et al. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer. 2012;64:34–40.PubMedCrossRef
47.
Zurück zum Zitat Ocvirk S, O'Keefe SJ. Influence of bile acids on colorectal cancer risk: Potential mechanisms mediated by diet - gut microbiota interactions. Curr Nutr Rep. 2017;6:315–22.PubMedPubMedCentralCrossRef Ocvirk S, O'Keefe SJ. Influence of bile acids on colorectal cancer risk: Potential mechanisms mediated by diet - gut microbiota interactions. Curr Nutr Rep. 2017;6:315–22.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Dermadi D, Valo S, Ollila S, et al. Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon. Cancer Res. 2017;77:3352–63.PubMedCrossRef Dermadi D, Valo S, Ollila S, et al. Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon. Cancer Res. 2017;77:3352–63.PubMedCrossRef
49.
Zurück zum Zitat Takahashi Y, Amano Y, Yuki T, et al. Impact of the composition of gastric reflux bile acids on Barrett's oesophagus. Dig Liver Dis. 2011;43:692–7.PubMedCrossRef Takahashi Y, Amano Y, Yuki T, et al. Impact of the composition of gastric reflux bile acids on Barrett's oesophagus. Dig Liver Dis. 2011;43:692–7.PubMedCrossRef
50.
Zurück zum Zitat Prichard DO, Byrne AM, Murphy JO, et al. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking. J Cell Mol Med. 2017;21:3612–25.PubMedPubMedCentralCrossRef Prichard DO, Byrne AM, Murphy JO, et al. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking. J Cell Mol Med. 2017;21:3612–25.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Bhat AA, Lu H, Soutto M, et al. Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1. Oncogene. 2018;37:6011–24.PubMedPubMedCentralCrossRef Bhat AA, Lu H, Soutto M, et al. Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1. Oncogene. 2018;37:6011–24.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Peng S, Huo X, Rezaei D, et al. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:G129–39.PubMedPubMedCentralCrossRef Peng S, Huo X, Rezaei D, et al. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:G129–39.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Banerjee B, Shaheen NJ, Martinez JA, et al. Clinical study of ursodeoxycholic acid in Barrett's esophagus patients. Cancer Prev Res (Phila). 2016;9:528–33.PubMedPubMedCentralCrossRef Banerjee B, Shaheen NJ, Martinez JA, et al. Clinical study of ursodeoxycholic acid in Barrett's esophagus patients. Cancer Prev Res (Phila). 2016;9:528–33.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Peery AF, Keku TO, Martin CF, et al. Distribution and characteristics of colonic diverticula in a United States screening population. Clin Gastroenterol Hepatol. 2016;14:980–5.PubMedPubMedCentralCrossRef Peery AF, Keku TO, Martin CF, et al. Distribution and characteristics of colonic diverticula in a United States screening population. Clin Gastroenterol Hepatol. 2016;14:980–5.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Flor N, Rigamonti P, Di Leo G, et al. Technical quality of CT colonography in relation with diverticular disease. Eur J Radiol. 2012;81:e250–e254254.PubMedCrossRef Flor N, Rigamonti P, Di Leo G, et al. Technical quality of CT colonography in relation with diverticular disease. Eur J Radiol. 2012;81:e250–e254254.PubMedCrossRef
56.
Zurück zum Zitat De Cecco CN, Ciolina M, Annibale B, et al. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC). Eur Radiol. 2016;26:639–45.PubMedCrossRef De Cecco CN, Ciolina M, Annibale B, et al. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC). Eur Radiol. 2016;26:639–45.PubMedCrossRef
Metadaten
Titel
Relationship between Barrett’s esophagus and colonic diseases: a role for colonoscopy in Barrett’s surveillance
verfasst von
Yuji Amano
Ryotaro Nakahara
Takafumi Yuki
Daisuke Murakami
Tetsuro Ujihara
Iwaki Tomoyuki
Ryota Sagami
Satoshi Suehiro
Yasushi Katsuyama
Kenji Hayasaka
Hideaki Harada
Yasumasa Tada
Youichi Miyaoka
Hirofumi Fujishiro
Publikationsdatum
25.06.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 11/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01600-x

Weitere Artikel der Ausgabe 11/2019

Journal of Gastroenterology 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.